Search the Newsreel

VIK|Viking Holdings Ltd|Price:99.612|Chg%:-0.738

Viking Holdings Ltd (VIK) exhibits relatively healthy fundamentals and significant growth potential, although its valuation is considered fair. Analysts have mostly issued "Buy" ratings with a target price of $104.603. Despite recent sideways trading, the company benefits from high institutional ownership and consistent revenue …

Viking Holdings Ltd (VIK) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Viking Holdings Ltd (VIK) stock information, focusing specifically on its dividend history. It states that Viking Holdings Ltd has distributed $0.00 in dividends over the past five years, indicating no recent dividend payouts or stock splits recorded for …

Truist Financial Maintains Viking Holdings(VIK.US) With Buy Rating, Maintains Target Price $102

Truist Financial has reiterated its Buy rating for Viking Holdings (VIK.US) and maintained a target price of $102. This indicates a continued positive outlook from the firm regarding Viking Holdings' stock performance and valuation.

Viking Therapeutics (VKTX.US) will release its earnings report after market close on July 29.

Viking Therapeutics (VKTX.US) is scheduled to release its earnings report after the market closes on July 29. Investors will be observing this announcement for insights into the company's financial performance.

Viking Holdings Ltd (VIK) Institutional Confidence

Viking Holdings Ltd (VIK) has an institutional shareholding score of 10.00, placing it first in the Hotels & Entertainment Services industry. The institutional shareholding proportion is 101.08%, which is a slight decrease from the previous quarter. Steven Cohen is the largest institutional shareholder, holding …

Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market

Viking Therapeutics, Inc. (VKTX) stock underperformed the broader market, falling 5.15% in the latest session compared to losses for the S&P 500, Dow, and Nasdaq. The company also underperformed the Medical sector over the past month. Investors are anticipating its upcoming earnings release on …

Viking Therapeutics (VKTX) Appoints Dorothy Gemmell To Board As Commercial Focus Grows

Viking Therapeutics (VKTX) has appointed Dorothy Gemmell, a healthcare executive with expertise in commercial execution and digital health, to its Board of Directors. This appointment signals a growing commercial focus for the clinical-stage biopharmaceutical company as it advances its pipeline in obesity and metabolic …

Bessemer Group Inc. Has $1.50 Million Stock Holdings in Viking Holdings Ltd. $VIK

Bessemer Group Inc. reduced its stake in Viking Holdings Ltd. by nearly 50% in the first quarter, holding 20,424 shares valued at approximately $1.5 million. Despite this, institutional investors collectively own 98.84% of Viking, with several other firms increasing their positions. Analysts maintain a …

Dorothy Gemmell Joins Viking Board After 25+ Years in Healthcare

Viking Therapeutics (NASDAQ: VKTX) has appointed Dorothy Gemmell to its Board of Directors, leveraging her over 25 years of experience in healthcare, digital health, and commercialization. Her expertise is expected to be crucial as Viking advances its metabolic pipeline, particularly in preparation for the …

Press Release: Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors

Viking Therapeutics has announced the appointment of Dorothy Gemmell to its Board of Directors, effective immediately. Gemmell brings extensive experience in commercialization leadership within the biotechnology industry, having held senior roles at companies like Genentech, Amgen, and Onyx Pharmaceuticals. Her expertise is expected to …

Viking Therapeutics’ Q2 results arrive after markets close

Viking Therapeutics (NASDAQ: VKTX) is scheduled to release its second-quarter 2026 financial results after market close on Wednesday, July 29, 2026. The company will also host a conference call on the same day at 4:30 p.m. Eastern Time to discuss the results and provide …

Citi Maintains Viking Holdings(VIK.US) With Buy Rating, Raises Target Price to $113

Citi has reiterated its Buy rating on Viking Holdings (VIK.US) and increased its target price to $113. This revised target price suggests a potential upside of 18.06% from the stock's last closing price. The adjustment reflects Citi's continued positive outlook on the company.

How Viking’s 2030 Oberammergau River Voyages Shape Its Experience-Led Investment Narrative At Viking (VIK)

Viking announced new 2030 Oberammergau Passion Play river voyages that include preferred seating and extended itineraries, reinforcing its strategy of securing long-lead, experience-driven bookings. This move supports Viking's significant fleet expansion plans, aiming to ensure high occupancy despite increased leverage and competition. While these …

Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm

Kuehn Law, PLLC is investigating whether officers and directors of Viking Therapeutics, Inc. (NASDAQ: VKTX) breached their fiduciary duties to shareholders through potential self-dealing. The firm is encouraging long-term VKTX stockholders to contact them for a free and no-obligation consultation to discuss potential damages …

Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026

Viking Therapeutics, Inc. announced it will release its financial results for the second quarter of 2026 after market close on Wednesday, July 29, 2026. The company will also host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the …

WCM Investment Management LLC Sells 35,164 Shares of Viking Holdings Ltd. $VIK

WCM Investment Management LLC significantly reduced its stake in Viking Holdings Ltd. by 39.7%, selling over 35,000 shares, though Viking continues to see strong institutional investment, with nearly 99% of the company owned by such entities. Despite a recent analyst downgrade to "hold," Viking …

Saatvik Green Energy And 2 Indian Growth Stocks With Strong Earnings Potential

Viking Holdings 1Q Loss $54.4M >VIK

Viking Holdings reported a first-quarter loss of $54.4 million. This financial update includes key earnings data for the period.

Goldman Sachs Maintains Viking Holdings (VIK) Neutral Recommendation

Goldman Sachs has reiterated its "Neutral" rating for Viking Holdings (VIK). The investment bank continues to hold a neutral stance on the company's stock.

Viking Holdings Ltd (VIK) Q4 2024 Earnings Report - Results, Call & Slides

Viking Holdings Ltd (VIK) reported its Q4 2024 earnings, surpassing analyst expectations with an actual EPS of $0.45 against a consensus of $0.36, and revenue of $1.35 billion, beating the expected $1.34 billion. The report details the company's past and estimated future earnings, including …

Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1

Key Points Viking Therapeutics just launched its next-gen weight loss program. Novo Nordisk and Eli Lilly are already deep into the development process with comparable programs. Viking's candidate is thus going to need to produce some stellar data to be competitive. 10 stocks we …

Should You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes."

Key Points The key trial results for VK2735 are still years away. There are some useful indicative results coming from a phase 1 maintenance trial over the next six or so months. VK2735 demonstrated the potential to generate relatively swift weight loss in phase …

Viking Holdings Price Target Raised to $115.00/Share From $100.00 by Jefferies

Jefferies has increased its price target for Viking Holdings (VIK) from $100.00 to $115.00 per share. This adjustment reflects an increased valuation for the company.

Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note

Viking Therapeutics (VKTX) stock performed strongly, gaining 1.95% while the broader market indices like the S&P 500, Dow, and Nasdaq fell. The company's stock has risen 19.72% over the past month, outperforming its sector and the S&P 500. Analysts expect Viking Therapeutics to report …

Viking Therapeutics (VKTX) Could Be 61% Undervalued As It Starts VK3019 Trial

Viking Therapeutics (VKTX) has initiated a Phase 1 study for VK3019, a potential weight loss therapy. Despite recent stock fluctuations, the company shows strong long-term momentum, with Simply Wall St's analysis suggesting it is 61% undervalued compared to a fair value of $92.72. However, …

Sandvik AB (SDVKF) Q2 2026 Earnings Call Highlights: Record Revenues and Strategic Growth ...

This article first appeared on GuruFocus. Total Order Intake: 37.8 billion, with organic growth of 17%. Total Revenues: 36.8 billion, with organic growth of 23%. Adjusted EBITDA: 8.3 billion, up from 5.6 billion, with a margin of 22.6%. Rolling 12-Month EBITDA Margin: 20.4%. Adjusted …

Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?

Viking Therapeutics (VKTX) is set to report its second-quarter 2026 earnings, with investors keenly focused on updates regarding its pipeline, particularly the obesity drug VK2735. The company's earnings have consistently missed estimates, and with no marketed drugs, revenue generation is not anticipated. Key areas …

Viking Holdings (VIK) Launches Oberammergau Itineraries, Does It Look Fully Valued?

Viking Holdings (VIK) has announced new 2030 river itineraries, including preferred access to the Oberammergau Passion Play, alongside a Summer Sale. The company's stock, trading at US$98.07, has seen significant year-to-date and one-year returns. While some intrinsic value estimates suggest the stock is undervalued, …

Law firm probes Viking Therapeutics officers for possible self-dealing harming shareholders

Kuehn Law, PLLC is investigating whether officers and directors of Viking Therapeutics, Inc. breached their fiduciary duties through potential self-dealing, which could result in shareholder damages. The firm is encouraging long-term shareholders to contact them for free consultations to protect their rights.

Viking’s 53-week Trend Signal pauses on 0.7x volume after a 30% quarter

Viking Holdings slipped 2.5% for the week, but the pullback came after a strong four-week advance and left the travel-services stock only 4.8% below its 52-week high.

Viking Therapeutics (VKTX) Stock Looks Stretched After a 6x Five Year Run

Why Viking Therapeutics (VKTX) Is Up 8.0% After Advancing New Obesity Drug VK3019 Into Phase 1 – And What's Next

Vikas Ecotech FY26 profit drops sharply on audit concerns

Solid Earnings Reflect Vikas Lifecare's (NSE:VIKASLIFE) Strength As A Business

Vikas Lifecare FY26 results face qualified audit opinion

Viking Mines (ASX:VKA) Divests Non-Core Gold Asset, Shifts Focus to Tungsten